Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : GenVec -- Ignore unavailable to you. Want to Upgrade?

To: Mark drummond who wrote (2)	5/4/1998 10:15:00 AM
From: Beltropolis Boy	Respond to of 19

mark. excellent. thanks for posting the link. those are the first hard numbers i've seen on genvec (i've just now requested an investor's packet). i should have noted the agreement you cited in my initial post; it is, however, indicated in the post article: "[GenVec] signed a deal worth more than $100 million last year to share its technology with the Parke-Davis Research Division of Warner-Lambert Co. of Morris Plains, N.J. The companies are working together to develop and market a treatment called BioByPass." if you don't mind me asking, was ipocentral the first place you noticed genvec? do you happen to know who are their major publicly traded competitors? from my limited due diligence, i've uncovered EntreMed (ENMD), also based in rockville, and Progenitor (PGEN). thanks again for the post, -chris.

To: Mark drummond who wrote (2)	5/4/1998 11:16:00 AM
From: Beltropolis Boy	Respond to of 19

mark. fwiw, here's another collaborative press release. i've snipped the first two paragraphs: GENVEC AND FUSO ANNOUNCE CANCER RESEARCH COLLABORATION ROCKVILLE, Md. and OSAKA, Japan, April 20 /PRNewswire/ -- GenVec, Inc. and Fuso Pharmaceutical Industries, Ltd. (Tokyo and Osaka: 4538) announced today the signing of a collaborative agreement for the research, development and commercialization of gene therapies for the treatment of human cancer. Under the agreement GenVec will receive product development related milestone payments and R&D funding for up to five years. In addition, at signature, Fuso purchased equity in GenVec. In return, Fuso receives commercialization rights in Japan, and an option for Korea and Taiwan for products developed under the collaboration. GenVec will receive royalties on any such products commercialized by Fuso, and GenVec retains the right to develop and commercialize the products throughout the rest of the world. pathfinder.com